Shares of AbbVie closed at a record after it struck a deal that will extend patent exclusivity for its blockbuster autoimmune ...

The news that the brand is protected from generics for more than a decade "gives AbbVie a kind of tremendous runway," to sell ...

We recently published 10 Stocks With Eye-Popping Gains; 7 Soar to Fresh Highs. Dianthus Therapeutics, Inc. (NASDAQ:DNTH) is ...

AbbVie shares rose 4% to a record high on Thursday after the U.S. drugmaker said it expected no generic competition for its ...

Now, you might be wondering if you’ve missed the boat, since ABBV stock is up 18% this year, trading at over $220 a share ...

On the FDA’s docket for the back half of September is Merck’s proposed subcutaneous formulation of its blockbuster cancer drug Keytruda.

Novo Nordisk, the drugmaker behind Ozempic, is laying off thousands of workers as it struggles against competition from other ...

AbbVie has signed deals with Rinvoq generic hopefuls as it extends protection for one of its prized assets until 2037.

(AP) Unlike scores of people who scrambled for the blockbuster drugs Ozempic and Wegovy to lose weight in recent years, Danielle Griffin had no trouble getting them. The 38-year-old information ...

The One Big Beautiful Bill Act created exemptions and delays to the negotiation of orphan drugs, which are poised to erode savings from negotiation by more than previous analyses suggested.

Two separate analyses in Health Affairs find the One Big Beautiful Bill creates a loophole that exempts or delays orphan ...

Columnist Teri Sforza writes that studies have found that the popular weight-loss and diabetes drugs reduced alcohol intake, binge drinking and relapse.